Yervoy (ipilimumab) / BMS 
Welcome,         Profile    Billing    Logout  
 197 Diseases   398 Trials   398 Trials   21826 News 


«12345678910111213...266267»
  • ||||||||||  Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
    Trial completion date, Trial primary completion date, Checkpoint inhibition:  IL13Ra2-CAR T Cells with or Without Nivolumab and Ipilimumab in Treating Patients with GBM (clinicaltrials.gov) -  Oct 9, 2024   
    P1,  N=60, Recruiting, 
    Suspended --> Recruiting Trial completion date: Jul 2025 --> Mar 2025 | Trial primary completion date: Jul 2024 --> Mar 2025
  • ||||||||||  Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
    Trial primary completion date, Checkpoint inhibition:  Immunotherapy + Radiation in Resectable Soft Tissue Sarcoma (clinicaltrials.gov) -  Oct 8, 2024   
    P1,  N=14, Active, not recruiting, 
    Similar cure rates were estimated for patients treated with IPI in both trials, despite staging and dosing differences. Trial primary completion date: Aug 2024 --> Aug 2025
  • ||||||||||  Trial completion date, Trial primary completion date:  Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma (clinicaltrials.gov) -  Oct 7, 2024   
    P1,  N=36, Recruiting, 
    Trial completion date: Sep 2024 --> Sep 2025 | Trial primary completion date: Sep 2024 --> Sep 2025 Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2023 --> Feb 2026
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
    Journal, Checkpoint inhibition:  Thromboembolism during immune checkpoint inhibitor therapy: frequency and risk factors. (Pubmed Central) -  Oct 6, 2024   
    Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2023 --> Feb 2026 These results suggested that the frequency of TE is higher than expected and should be considered and monitored in patients treated with ICIs.
  • ||||||||||  Kimmtrak (tebentafusp-tebn) / Immunocore, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
    Retrospective data, Journal, PD(L)-1 Biomarker, IO biomarker, Metastases:  Immunotherapy response and resistance in patients with advanced uveal melanoma: a retrospective cohort study. (Pubmed Central) -  Oct 5, 2024   
    ImPERCIST5 and RECIST v1.1 are valuable tools in the radiological response assessment, but both methods display limitations. Accurate biomarkers to stratify patients at risk for disease progression and future translational studies to investigate mechanisms of response and resistance are required.
  • ||||||||||  Yervoy (ipilimumab) / BMS
    Tertiary lymphoid structure signature in digital H&E slides as a prognostic biomarker in cutaneous melanoma (Grand Ballroom AB - George R. Brown Convention Center) -  Oct 4, 2024 - Abstract #SITC2024SITC_1862;    
    P3
    (NCT01274338).1 The multi-resolution HookNet model implemented in HookNet-TLS leverages both contextual information and high-resolution details to identify structures visible at lower magnifications and capture subtle differences at higher magnifications...The significant correlation between higher normalized TLS density and improved OS underscores the prognostic value of TLS in cancer immunotherapy. These findings highlight the potential of AI-driven approaches to standardize TLS assessment using low-cost H&E staining, which has a great translational impact in real-world practice.
  • ||||||||||  relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
    Spatially resolved immunologic hallmarks of response to neoadjuvant immune checkpoint blockade in metastatic melanoma (Grand Ballroom AB - George R. Brown Convention Center) -  Oct 4, 2024 - Abstract #SITC2024SITC_1803;    
    Ongoing analyses are investigating markers of ER stress in T cells and myeloid cells and these will be updated at the meeting. Methods We assembled a retrospective cohort of 68 patients with stage 3 melanoma: 35 NICB (Ipilimumab-nivolumab, nivolumab-relatlimab, nivolumab) (14 complete response, 5 partial response, 14 non-response) and 33 treatment-na
  • ||||||||||  relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
    Spatially resolved immunologic hallmarks of response to neoadjuvant immune checkpoint blockade in metastatic melanoma (Exhibit Halls AB - George R. Brown Convention Center) -  Oct 4, 2024 - Abstract #SITC2024SITC_1720;    
    Further tolerability and antitumor activity will be evaluated in pts with advanced malignancies. Methods We assembled a retrospective cohort of 68 patients with stage 3 melanoma: 35 NICB (Ipilimumab-nivolumab, nivolumab-relatlimab, nivolumab) (14 complete response, 5 partial response, 14 non-response) and 33 treatment-na
  • ||||||||||  Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
    Immunological impact of cytoreductive nephrectomy in combination with immune checkpoint inhibitors in metastatic renal cell carcinoma: insights from the SEVURO-CN trial (Exhibit Halls AB - George R. Brown Convention Center) -  Oct 4, 2024 - Abstract #SITC2024SITC_1697;    
    P=N/A, P3
    This information is clearly stated in the consent form.Download figure Open in new tab Download powerpoint Abstract 176 Figure 1 Study flowchart of (A) SEVURO-CN trial and (B) collected study samples in this study. CN, cytoreductive nephrectomy; IMDC, International mRCC Database Consortium; Ipi, ipilimumab; mRCC, metastatic renal cell carcinoma; Nivo, nivolumab; KPS, Karnofsky performance statusDownload figure Open in new tab Download powerpoint Abstract 176 Figure 2 UMAP plot of (A) all cells from pooled samples clustered by the cell types, and (B) density heatmap of each subgroup according to different time points
  • ||||||||||  Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
    Application of a novel multiplex imaging-based immunotherapy panel and AI-powered analysis solution for spatial biomarker identification on immunotherapy-treated melanoma patients (Exhibit Halls AB - George R. Brown Convention Center) -  Oct 4, 2024 - Abstract #SITC2024SITC_1647;    
    P2
    SECOMBIT is registered at ClinicalTrials.gov (NCT02631447). The study design and conduct complied with all current regulations regarding the use of human study participants and was conducted in accordance with the criteria set by the Declaration of Helsinki.Download figure Open in new tab Download powerpoint Abstract 117 Figure 1 A novel immunotherapy-focused multiplex imaging panelDownload figure Open in new tab Download powerpoint Abstract 117 Figure 2 Spatially resolved multiplex imaging analysis pipeline for biomarker identification
  • ||||||||||  Yervoy (ipilimumab) / BMS
    Associations of somatic mutations and other genetic alterations with survival outcome following CTLA4 blockade in melanoma patients (Exhibit Halls AB - George R. Brown Convention Center) -  Oct 4, 2024 - Abstract #SITC2024SITC_1567;    
    Furthermore, the wild-type ANKHD1?EIF4EBP3 gene was associated with significantly better progression-free survival (PFS) and OS compared to patients with mutated genes (p<0.05). Conclusions Our investigation identified significant associations between genomic alterations in melanoma and clinical outcomes following neoadjuvant ipilimumab that warrant investigation in the context of other ICIs.
  • ||||||||||  Yervoy (ipilimumab) / BMS
    VCAM-1+ tumor associated macrophages form perivascular tumor niches and drive resistance to anti-CTLA-4 therapy (George R. Brown Convention Center - Level 3 - Grand Ballroom B) -  Oct 4, 2024 - Abstract #SITC2024SITC_1490;    
    Publicly available bulk RNAseq datasets derived from melanoma patients treated with ipilimumab were used to assess patient overall survival bearing VCAM-1+ TAM gene signature...Finally, Spatiotemporal analysis using multiplexed imaging revealed that VCAM-1+ TAMs form perivascular niches and spatially colocalize with exhausted-like TOX+ CD8 T cells at later timepoints in B16F10 tumors. Conclusions Collectively, our findings uncover VCAM-1+ TAMs as negative regulators of T cells and whose abundance correlates with anti-CTLA-4 resistance in mice and humans.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Erbitux (cetuximab) / Eli Lilly, Yervoy (ipilimumab) / BMS
    3D ex vivo patient tissue platform feasibility for testing drug responses in primary and metastatic colorectal cancer (Exhibit Halls AB - George R. Brown Convention Center) -  Oct 4, 2024 - Abstract #SITC2024SITC_1431;    
    Minimally processed tumor was embedded in a protein-rich hydrogel and subjected to dose-ranges of therapies including chemotherapy (5-FU, carboplatin), targeted therapies (Cetuximab) and immunotherapies (pembrolizumab, ipilimumab) and relevant controls (SEA, CD3/CD28 beads, staurosporine)...Conclusions This study evaluated the 3D EVPT platform for testing drug responses in primary and metastatic CRC samples. The platform successfully preserved the TME and allowed for the assessment of various therapies, including chemotherapy treatments, targeted therapies, and immunotherapies.
  • ||||||||||  Yervoy (ipilimumab) / BMS
    Modulating T cell function with small molecules targeting CTLA-4 for improved immunotherapy (Exhibit Halls AB - George R. Brown Convention Center) -  Oct 4, 2024 - Abstract #SITC2024SITC_1311;    
    Ipilimumab, the ICI targeting CTLA-4 has noteworthy irAEs and acquired resistance...By successfully expressing and purifying physiologically relevant proteins, we ensured the validity of our screening process. These findings highlight the potential for developing small molecule inhibitors as a safer and more versatile alternative to monoclonal antibodies and lays the foundation for the development of a novel class of immunotherapy drugs.Download figure Open in new tab Download powerpoint Abstract 1286 Figure 1 Download figure Open in new tab Download powerpoint Abstract 1286 Figure 2 Download figure Open in new tab Download powerpoint Abstract 1286 Figure 3 Download figure Open in new tab Download powerpoint Abstract 1286 Figure 4 Download figure Open in new tab Download powerpoint Abstract 1286 Figure 5 Download figure Open in new tab Download powerpoint Abstract 1286 Figure 6
  • ||||||||||  brenetafusp (IMC-F106C) / Immunocore
    Phase 1 safety and efficacy of brenetafusp, a PRAME  (Exhibit Halls AB - George R. Brown Convention Center) -  Oct 4, 2024 - Abstract #SITC2024SITC_1045;    
    P1/2, P3
    Ethics Approval The study was approved by the Institutional Review Board/Independent Ethics Committee of each study site and followed the Declaration of Helsinki and International Conference on Harmonisation Good Clinical Practice guidelines. All patients provided written informed consent before any study procedures were performed.
  • ||||||||||  Yervoy (ipilimumab) / BMS
    In situ rAPMV-4 tumor vaccination achieves complete responses, long-term antitumor immunity with systemic tumor clearance, priming response to sub-therapeutic dosing of aCTLA-4 in colorectal carcinoma (Exhibit Halls AB - George R. Brown Convention Center) -  Oct 4, 2024 - Abstract #SITC2024SITC_985;    
    Considering the observed induction of immune signatures associated with response to CTLA-4 blockade by APMV-4, as well as some clinical precedent for use of Ipilimumab in CRC, we strategically developed a combinatorial treatment regimen to supplement APMV-4 in situ vaccination with a single, low-dose administration of aCTLA-4...Conclusions All in all, the described combinatorial approach serves as a proof-of-principle for future translation to the clinic, as co-administration with APMV-4 will allow for reduced dosage and frequency of CTLA-4-blocking antibodies. Ultimately, this will prevent development of life-threatening adverse effects that currently limit aCTLA-4 usage in the clinic, while maximizing likelihood of response to therapy.
  • ||||||||||  Avastin (bevacizumab) / Roche, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
    Anti-angiogenics enhance immune checkpoint inhibitor efficacy in ovarian cancer (Exhibit Halls AB - George R. Brown Convention Center) -  Oct 4, 2024 - Abstract #SITC2024SITC_982;    
    Ethics Approval Surgical or biopsy samples were obtained with informed consent from the Hospital of the University of Pennsylvania in accordance with IRB (#702679). PDX studies were carried out in accordance with the animal ethics guidelines approved by the University of Pennsylvania; vania IACUC protocol (#806002)and in the regulations of the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC).
  • ||||||||||  Clinical response to immune checkpoint inhibitor therapy in metastatic and unresectable NF1 mutated cutaneous melanoma (Exhibit Halls AB - George R. Brown Convention Center) -  Oct 4, 2024 - Abstract #SITC2024SITC_977;    
    The research could not practicably be conducted without the waiver or alteration 3. The research could not practicably be conducted without access to and use of the requested information.View this table:View inline View popup Download powerpoint Abstract 557 Table 1 Progression free survival and overall survival with ICI therapy in NF1-mutated vs. NF1-WT melanomaDownload figure Open in new tab Download powerpoint Abstract 557 Figure 1 Progression free survival in NF1-mutated melanoma compared to NF1-WT melanoma patientsDownload figure Open in new tab Download powerpoint Abstract 557 Figure 2 Overall survival in NF1-mutated melanoma compared to NF1-WT melanoma patients
  • ||||||||||  Opdivo (nivolumab) / BMS, Tecentriq (atezolizumab) / Roche, Yervoy (ipilimumab) / BMS
    Immune checkpoint inhibitors in advanced urachal and non-urachal adenocarcinomas of the urinary tract: the MD Anderson Cancer Center experience (Exhibit Halls AB - George R. Brown Convention Center) -  Oct 4, 2024 - Abstract #SITC2024SITC_973;    
    Ethics Approval The study was performed in accordance with PA16-0736 protocol, approved by MD Anderson Cancer Center Institutional Review Board. The protocol is an investigational low-risk study with consent waiver for all participants (retrospective series with no identifiable patient information or clinical care-changing information).View this table:View inline View popup Download powerpoint Abstract 516 Table 1 Baseline characteristics and outcomes of interest in our cohort (n=22), categorized by adenocarcinoma subtype (urachal [UA] and non-urachal [NUA])
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
    Clinical benefit of adding radiation in immunotherapy-refractory Merkel cell carcinoma among 41 patients (Exhibit Halls AB - George R. Brown Convention Center) -  Oct 4, 2024 - Abstract #SITC2024SITC_972;    
    Ethics Approval This retrospective study involving human health data was approved by the Fred Hutchinson Cancer Center Institutional Review Board (ID #6585). All participants gave informed consent before participating.Download figure Open in new tab Download powerpoint Abstract 783 Figure 1 PFS of RT cohort vs comparison cohort
  • ||||||||||  Tirazone (tirapazamine) / Teclison, SRI International, evofosfamide (IMGS-101) / ImmunoGenesis, Yervoy (ipilimumab) / BMS
    Hypoxia-activated prodrugs with distinct mechanisms of action sensitize murine prostate tumors to immune checkpoint blockade (Exhibit Halls AB - George R. Brown Convention Center) -  Oct 4, 2024 - Abstract #SITC2024SITC_940;    
    Methods We investigated the efficacy of evofosfamide, AQ4N (Banoxantrone) and TPZ (Tirapazamine), three HAP with distinct mechanisms of action, for their ability to reduce tumor hypoxia, drive tumor regression and sensitize murine prostate tumors to ICB...We found that despite distinct mechanisms of action and apparently independent of their ability to suppress macroscopic tumor hypoxia, HAP influence diverse cell types in the TME by reducing tumor cell viability and metabolism, repolarizing immune suppressive myeloid stroma and promoting T cell function. Ethics Approval All procedures were conducted in accordance with the guidelines established by the University of Texas MD Anderson Cancer Center Institutional Animal Care and Use Committee.
  • ||||||||||  relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
    Clustering by metastatic sites predicts overall survival and describes patterns of progression for patients with metastatic melanoma after immunotherapy (Exhibit Halls AB - George R. Brown Convention Center) -  Oct 4, 2024 - Abstract #SITC2024SITC_885;    
    Methods This retrospective study utilized the US-based Flatiron Health electronic health record-derived de- identified databaseincluding patients with metastatic melanoma treated first-line with immunotherapy (ipi/nivo, anti-PD1 monotherapy, or nivo+relatlimab)...These clusters may represent a novel schema for risk stratifying metastatic melanoma. Ethics Approval This study was approved by the Yale University Institutional Review Board, IRB ID 2000036075.View this table:View inline View popup Download powerpoint Abstract 559 Table 1 Patient demographicsView this table:View inline View popup Download powerpoint Abstract 559 Table 2 Characteristics by clusterDownload figure Open in new tab Download powerpoint Abstract 559 Figure 1 Download figure Open in new tab Download powerpoint Abstract 559 Figure 2 Download figure Open in new tab Download powerpoint Abstract 559 Figure 3
  • ||||||||||  muzastotug (ADG126) / Adagene
    Phase 1b/2, multicenter dose escalation and expansion study of muzastotug (ADG126, a masked anti-CTLA-4 SAFEbody (Exhibit Halls AB - George R. Brown Convention Center) -  Oct 4, 2024 - Abstract #SITC2024SITC_880;    
    P1/2
    A higher dose Muza (20 mg/kg) allows for a rapid reaching of plasma cleaved drug exposure associated with clinical efficacy and an acceptable safety profile when combined with pembrolizumab. This regimen potentially can offer a best-in-class treatment option for patients with advanced/metastasis MSS CRC.View this table:View inline View popup Download powerpoint Abstract 744 Table 1 Safety and efficacy evaluable patients by dose levels
  • ||||||||||  ADG116 / Adagene, muzastotug (ADG126) / Adagene
    Deciphering improved clinical therapeutic index (TI) of Muzastotug (ADG126), a masked anti-CTLA-4 SAFEbody (Exhibit Halls AB - George R. Brown Convention Center) -  Oct 4, 2024 - Abstract #SITC2024SITC_879;    
    ADG116, an IgG1 monoclonal antibody targeting a unique epitope of CTLA-4 which is conserved across species, has demonstrated improved TI over ipilimumab via enhanced epitope-dependent ADCC and T cell priming...When combined with toripalimab, muzastotug at 10 mg/kg Q3W showed significantly better safety and similar efficacy versus ADG116 at 3 mg/kg Q6W (highest tolerable regimen)...Modeling predicts a significantly higher and sustained SS tumor-specific engagement of CTLA-4 by muzastotug in patients. The potential best-in-class profile of muzastotug supports further clinical development.1